Table 1.
Clinical, demographic, and MSCT data of the entire MSCT cohort (n = 67)
| Entire cohort (n = 67) | ||
|---|---|---|
| Women |
[n,%] |
35, 52% |
| Median age (range) |
[years] |
61 (21 – 87) |
| Median BMI (range) |
[kg/m2] |
24 (17 – 53) |
| Median time ESRD (range) |
[months] |
49 (2 – 364) |
| Previous renal transplant |
[n,%] |
21, 31% |
| Current smoking |
[n,%] |
10, 15% |
| History of CVD |
[n,%] |
25, 37% |
| History of CAD |
[n,%] |
22, 33% |
| Diabetes |
[n,%] |
15, 22% |
| History of PAD |
[n,%] |
9, 13% |
| History of MI |
[n,%] |
9, 13% |
| History of PTex |
[n,%] |
9, 13% |
| Median CAC Agatston (range) (n = 65) |
|
279 (0 – 3736) |
| Median Mass CAC (range) (n = 65) |
|
51 (0 – 643) |
| Median Volume CAC (range) (n = 65) |
|
261 (0 – 3267) |
| Median AVC Agatston (range) |
|
0 (0 – 1596) |
| Median Mass AVC (range) |
|
0 (0 – 284) |
| Median Volume AVC (range) |
|
0 (0 – 1316) |
| CAC Agatston score >100 |
[n,%] |
44, 66% |
| Any AVC |
[n,%] |
27, 40% |
| Usage of Phosphate binders |
[n,%] |
61, 92% |
| Calcium-based |
[n,%] |
51, 77% |
| Aluminum-based |
[n,%] |
14, 22% |
| Calcimimetics | [n,%] | 16, 25% |
Abbreviations: AVC aortic valve calcification; BMI body mass index; CAC coronary artery calcification; CAD coronary artery disease; CVD cerebrovascular disease; ESRD end-stage renal disease; MI myocardial infarction; MSCT multi-sclice computed tomography; PAD peripheral arterial disease; Ptex parathyroidectomy.